Innovations in steroid chemistry, pharmacodynamic biomarkers, clinical trial design, and business models for orphan drug development
Phase 1 biomarker data shows improvement of safety profiles of vamorolone over prednisolone for adrenal suppression, bone turnover, insulin resistance, and immune suppression. Learn more >
Vamorolone enrollment in Phase 2a opens at Duke University; first DMD subjects enrolled.
microRNAs shown to define dystrophin levels in patient muscle (Fiorillo et al. 2015) – IP licensed to ReveraGen.
Enrollment has begun in the Phase 2a clinical trial of vamorolone (VBP15) in the treatment of boys with Duchenne muscular dystrophy (DMD). The Phase 2a trial sponsored by ReveraGen BioPharma, is an open-label, multiple ascending dose study that will be